Article Text

Download PDFPDF
P193 p53 and p16 expression profiles identify three prognostically subgroups in vulvar cancer: a TMA based study by the AGO-CaRE-translational study group
  1. L Wölber1,
  2. K Prieske1,
  3. C Eulenburg1,
  4. N de Gregorio2,
  5. R Klapdor3,
  6. M Kalder4,
  7. I Braicu5,
  8. S Fuerst6,
  9. M Klar7,
  10. H-G Strauss8,
  11. G Mehlhorn9,
  12. W Meier10,
  13. A Ignatov11,
  14. A Mustea12,
  15. J Jueckstock13,
  16. G Schmidt14,
  17. D Bauerschlag15,
  18. M Hellriegel16,
  19. U Canzler17,
  20. A Luyten18,
  21. S Kommoss19,
  22. P Hantschmann20,
  23. M Heubner21,
  24. S Mahner13,
  25. E Burandt1 and
  26. AGO Study Group
  1. 1University Medical Center Hamburg-Eppendorf, Hamburg
  2. 2University Hospital Ulm, Ulm
  3. 3University Medical School Hannover, Hannover
  4. 4University Hospital Marburg, Marburg
  5. 5Charité University Medicine Berlin Campus Virchow, Berlin
  6. 6University of Munich (LMU), Munich
  7. 7University Hospital Freiburg, Freiburg
  8. 8University of Halle, Halle
  9. 9Erlangen University Hospital, Erlangen
  10. 10Evangelisches Krankenhaus Duesseldorf, Duesseldorf
  11. 11University of Magdeburg, Magdeburg
  12. 12University Medicine Greifswald, Greifswald
  13. 13University of Munich
  14. 14University Hospital Technical University of Munich, Munich
  15. 15University Medical Center Kiel, Kiel
  16. 16Georg-August-University Goettingen, Goettingen
  17. 17Technische Universität Dresden, Dresden
  18. 18Wolfsburg Hospital, Wolfsburg
  19. 19University Hospital Tuebingen, Tuebingen
  20. 20Hospital Altoettingen, Altoettingen
  21. 21University Hospital Essen, Essen, Germany


Introduction/Background Today, there are two accepted pathways for tumorigenesis of vulvar squamous cell carcinoma (VSCC): an HPV-dependent with p16 overexpression as a surrogate for HPV-associated transformation and an HPV-independent route linked to lichen sclerosus, characterized by p53 mutation. A possible correlation of HPV dependency with a favourable prognosis has been proposed.

Methodology The AGO CaRE-1 study is a retrospective survey of pts with primary VSCC FIGO stage ≥1B (UICC-TNM version 6) treated at 29 gynecologic cancer centers in Germany 1998–2008 (n=1,618). For this CaRE-translational sub-study available FFPE tissue was collected centrally (n=648). A tissue micro array (TMA) was constructed; p16 and p53 expression was determined by immunohistochemistry (IHC). HPV status and subtype were analyzed by PCR.

Results p16 IHC was interpretable in 550 TMA spots and considered positive in 166/550 (30.2%). HPV DNA was detected in 78.4% of the p16+ tumors, with HPV 16 being the most common subtype (88.3%). p53 IHC was interpretable in 597 spots, 187/597 (31.3%) were considered positive. Pts with p53+ tumors were older at first diagnosis (71 vs. 66 yrs; p=0.001 for p53- tumors) and showed lymph-node involvement more often (43.3% vs. 31.1%; p=0.007). There was a relevant number of tumors with neither p16 nor p53 overexpression (221/535); while co-expression of p53 and p16 was rare (12/535). For survival analyses, three groups were defined: p53+ (n=163), p16+/p53- (n=151) and p16-/p53- (n=221). 2-y-disease-free (DFS) and overall survival (OS) rates were significantly different between the groups: DFS: p53+ 47.0%; p16-/p53- 53% and p16+/p53- 65.5% (p<0.001); OS: 70.4%, 72.6% and 82.7% (p=0.003), respectively. Adjustment for age and nodal status showed consistent p16 and p53 effects regarding DFS.

Conclusion p16 overexpression is associated with an improved prognosis in VSCC while p53 positivity is linked to an adverse outcome. Our data provide evidence of a clinically.

Disclosure The AGO CaRE translational study was supported by medac oncology without restrictions in the study protocol.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.